Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

Core Insights - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] Group 1: Company Overview - Liquidia's current focus includes the development and commercialization of products for pulmonary hypertension and other applications of its proprietary PRINT Technology [3] - The lead candidate, YUTREPIA™ (treprostinil) inhalation powder, is an investigational drug aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3] Group 2: Upcoming Events - The Chief Financial Officer and Chief Operating Officer, Michael Kaseta, along with Chief Medical Officer, Rajeev Saggar, will provide a business update at the BofA Securities 2025 Health Care Conference on May 13, 2025 [1] - The event will be accessible via a webcast on Liquidia's website, with an archived version available for at least 30 days post-event [2]